Clinical Trial Update: Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and immunogenicity of a single dose of GSK134612 in children aged 12-14 months and 3-5 years, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• GSK134612 (Meningococcal vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 2 | Status: COMPLETED | Results posted: 2017-03-01